Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-20T11:35:13.510Z Has data issue: false hasContentIssue false
  • English
  • Français

Experience of Healthcare Workers Taking Postexposure Prophylaxis After Occupational HIV Exposures: Findings of the HIV Postexposure Prophylaxis Registry

Published online by Cambridge University Press:  02 January 2015

David Weber ,
Susan A. Wang ,
Adelisa L. Panlilio ,
Peggy A. Doi ,
Alice D. White ,
Michael Stek Jr ,
Alfred Saah  and
HIV PEP Registry Group
Susan A. Wang*
Affiliation:
HIV Infections Branch, Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia Epidemic Intelligence Service, Epidemiology Program Office, CDC, Atlanta, Georgia
Adelisa L. Panlilio
Affiliation:
HIV Infections Branch, Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia
Peggy A. Doi
Affiliation:
PharmaResearch Corporation, Wilmington, North Carolina
Alice D. White
Affiliation:
Glaxo Wellcome Inc, Research Triangle Park, North Carolina
Michael Stek Jr
Affiliation:
Merck & Co, Inc, West Point, Pennsylvania
Alfred Saah
Affiliation:
Merck & Co, Inc, West Point, Pennsylvania
*
Mailstop EO2, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To collect information about the safety of taking antiretroviral drugs for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP).

Design:

A voluntary, confidential registry.

Setting:

Hospital occupational health clinics, emergency departments, private physician offices, and health departments in the United States.

Results:

492 healthcare workers (HCWs) who had occupational exposures to HIV, were prescribed HIV PEP, and agreed to be enrolled in the registry by their healthcare providers were prospectively enrolled in the registry. Three hundred eight (63%) of 492 of the PEP regimens prescribed for these HCWs consisted of at least three antiretroviral agents. Of the 449 HCWs for whom 6-week follow-up was available, 195 (43%) completed the PEP regimen as initially prescribed. Forty-four percent (n=197) of HCWs discontinued all PEP drugs and did not complete a PEP regimen. Thirteen percent (n=57) discontinued ≥1 drug or modified drug dosage or added a drug but did complete a course of PEP. Among the 254 HCWs who modified or discontinued the PEP regimen, the two most common reasons for doing so were because of adverse effects attributed to PEP (54%) and because the source-patient turned out to be HIV-negative (38%). Overall, 340 (76%) HCWs with 6-week follow-up reported some symptoms while on PEP: nausea (57%), fatigue or malaise (38%), headache (18%), vomiting (16%), diarrhea (14%), and myalgias or arthralgias (6%). The median time from start of PEP to onset of each of the five most frequently reported symptoms was 3 to 4 days. Only 37 (8%) HCWs with 6-week follow-up were reported to have laboratory abnormalities; review of the reported abnormalities revealed that most were unremarkable. Serious adverse events were reported to the registry for 6 HCWs; all but one event resolved by the 6-month follow-up visit. Fewer side effects were reported by HCWs taking two-drug PEP regimens than by HCWs taking three-drug PEP regimens.

Conclusions:

Side effects from HIV PEP were very common but were rarely severe or serious. The nature and frequency of HIV PEP toxicity were consistent with information already available on the use of these antiretroviral agents. Clinicians prescribing HIV PEP need to counsel HCWs about PEP side effects and should know how to manage PEP toxicity when it arises.

Type
Topics in Occupational Medicine
Information
Infection Control & Hospital Epidemiology , Volume 21 , Issue 12 , December 2000 , pp. 780 - 785
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Centers for Disease Control and Prevention. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR 1996;45:468–480.Google Scholar
2.Centers for Disease Control and Prevention. Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR 1990;39(RR-1):1–14.Google Scholar
3.Cardo, DM, Culver, DH, Ciesielski, CA, Srivastava, PU, Marcus, R, Abiteboul, D, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997;337:1485–1490.Google Scholar
4.Connor, EM, Sperling, RS, Gelber, R, Kiselev, P, Scott, G, O'Sullivan, MJ, et al. Reduction of maternal infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173–1180.Google Scholar
5.Tsai, CC, Follis, KE, Sabo, A, Beck, TW, Grant, RF, Bischofberger, N, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonyl-methoxypropyl) adenine. Science 1995;270:1197–1199.CrossRefGoogle Scholar
6.Böttiger, D, Johansson, NG, Samuelsson, B, Zhang, H, Putkonen, P, Vrang, L, et al. Prevention of simian immunodeficiency virus, SIVsm, or HrV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. AIDS 1997;11:157–162.Google Scholar
7.Manion, DJ, Hirsch, MS. Combination chemotherapy for human immunodeficiency virus-1. Am J Med 1997;102(suppl 5B):76–80.CrossRefGoogle ScholarPubMed
8.Lafeuillade, A, Poggi, C, Tamalet, C, Profizi, N, Tourres, C, Costes, O. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis 1997;175:1051–1055.Google Scholar
9.Food and Drug Administration. Department of Health and Human Services. Records and reports concerning adverse drug experiences on marketed prescription drugs for human use without approved new drug applications (21 CFR 310.305). Federal Register revised April 1, 1998;5:121–124.Google Scholar
10.Tokars, JI, Marcus, R, Culver, DH, Schable, CAMcKibben, PS, Bandea, CI, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. The CDC Cooperative Needlestick Surveillance Group. Ann Intern Med 1993;118:913–919.CrossRefGoogle ScholarPubMed
11.US Department of Labor. Bureau of Labor Statistics. Employment and Earnings: Labor Force Statistics from the Current Population Survey. Washington, DC: Bureau of Labor Statistics; 1998.Google Scholar
12.Robillard, P, Roy, E, Pineault, M. Follow-up of health care workers (HCWs) and prophylaxis after an occupational exposure to HIV: a no show. Twelfth World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 33177.Google Scholar
13.Russi, M, Buitrago, M, Perlotto, J, Van Rhijn, D, Nash, G, Friedland, G, et al. Antiretroviral prophylaxis of occupationally exposed health care workers at two large urban medical centers. Twelfth World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 33178.Google Scholar
14.Sepkowitz, KA, Rivera, P, Louther, J, Lim, S, Pryor, B. Postexposure prophylaxis for human immunodeficiency virus: frequency of initiation and completion of newly recommended regimen. Infect Control Hosp Epidemiol 1998;19:506–508.CrossRefGoogle ScholarPubMed
15.Koll, B, Raucher, B, Nadig, R, Flynn, A, Knowlton, K, and the NaSH Surveillance Group. HIV postexposure prophylaxis. In: Program and Abstracts of the Infectious Diseases Society of America 35th Annual Meeting; September 13-16, 1997; San Francisco, CA Alexandria, VA: Infectious Diseases Society of America, 1997:161. Abstract 479.Google Scholar
16.Swotinsky, RB, Steger, KASulis, C, Snyder, S, Craven, DE. Occupational exposure to HIV: experience at a tertiary care center. J Occup Environ Med 1998;40:1102–1109.CrossRefGoogle ScholarPubMed
17.Gerberding, JL, Fahrner, R, Beekman, SE, Nelson, L, Perlman, JL, Henderson, DK. Combination post-exposure prophylaxis (PEP): a prospective study of HIV-exposed health care workers (HCW). Twelfth World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 33175.Google Scholar
18.Wang, SA, Puro, V. Toxicity of post-exposure prophylaxis for human immunodeficiency virus. In: Panlilio, AL, Cardo, DM, eds. Baillières Clinical Infectious Diseases, Prevention Strategies for Health Care Workers. London, UK: Bafflière Tindall; 1999:349–363.Google Scholar
19.Centers for Disease Control and Prevention. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR 1998;47(RR-7):1–33.Google Scholar